These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 28400191)

  • 1. Impact of Pulmonary Capillary Wedge Pressure on Long-Term Mortality in Patients With Pulmonary Arterial Hypertension Treated With Parenteral Trepostinil.
    Patel JK; Rao Y; Strachan P
    Heart Lung Circ; 2018 Feb; 27(2):183-189. PubMed ID: 28400191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current epoprostenol use in patients with severe idiopathic, heritable or anorexigen-associated pulmonary arterial hypertension: data from the French pulmonary hypertension registry.
    Bergot E; Sitbon O; Cottin V; Prévot G; Canuet M; Bourdin A; de Groote P; Rottat L; Gressin V; Jaïs X; Humbert M; Simonneau G
    Int J Cardiol; 2014 Apr; 172(3):561-7. PubMed ID: 24529947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact on survival of warfarin in patients with pulmonary arterial hypertension receiving subcutaneous treprostinil.
    Ascha M; Zhou X; Rao Y; Minai OA; Tonelli AR
    Cardiovasc Ther; 2017 Oct; 35(5):. PubMed ID: 28643420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Children with pulmonary arterial hypertension and prostanoid therapy: long-term hemodynamics.
    Siehr SL; Ivy DD; Miller-Reed K; Ogawa M; Rosenthal DN; Feinstein JA
    J Heart Lung Transplant; 2013 May; 32(5):546-52. PubMed ID: 23453572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials.
    Benza RL; Gomberg-Maitland M; Naeije R; Arneson CP; Lang IM
    J Heart Lung Transplant; 2011 Sep; 30(9):982-9. PubMed ID: 21531577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transition from parenteral to oral treprostinil in pulmonary arterial hypertension.
    Chakinala MM; Feldman JP; Rischard F; Mathier M; Broderick M; Leedom N; Laliberte K; White RJ
    J Heart Lung Transplant; 2017 Feb; 36(2):193-201. PubMed ID: 27469018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demographics and outcomes of patients diagnosed with pulmonary hypertension with pulmonary capillary wedge pressures 16 to 18 mm Hg: insights from the REVEAL Registry.
    Frost AE; Farber HW; Barst RJ; Miller DP; Elliott CG; McGoon MD
    Chest; 2013 Jan; 143(1):185-195. PubMed ID: 22661451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of inhaled treprostinil for the treatment of pulmonary arterial hypertension in children.
    Krishnan U; Takatsuki S; Ivy DD; Kerstein J; Calderbank M; Coleman E; Rosenzweig EB
    Am J Cardiol; 2012 Dec; 110(11):1704-9. PubMed ID: 22917554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial.
    Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ;
    Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry.
    Badesch DB; Raskob GE; Elliott CG; Krichman AM; Farber HW; Frost AE; Barst RJ; Benza RL; Liou TG; Turner M; Giles S; Feldkircher K; Miller DP; McGoon MD
    Chest; 2010 Feb; 137(2):376-87. PubMed ID: 19837821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension.
    Tokunaga N; Ogawa A; Ito H; Matsubara H
    J Cardiol; 2016 Dec; 68(6):542-547. PubMed ID: 27005767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Usefulness of pulmonary capillary wedge pressure as a correlate of left ventricular filling pressures in pulmonary arterial hypertension.
    Oliveira RK; Ferreira EV; Ramos RP; Messina CM; Kapins CE; Silva CM; Ota-Arakaki JS
    J Heart Lung Transplant; 2014 Feb; 33(2):157-62. PubMed ID: 24268673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Totally Implantable IV Treprostinil Therapy in Pulmonary Hypertension Assessment of the Implantation Procedure.
    Waxman AB; McElderry HT; Gomberg-Maitland M; Burke MC; Ross EL; Bersohn MM; Pangarkar SS; Tarver JH; Zwicke DL; Feldman JP; Chakinala MM; Frantz RP; Thompson GB; Torres F; Rauck RL; Clagg K; Durst L; Li P; Morris M; Southall KL; Peterson L; Bourge RC
    Chest; 2017 Dec; 152(6):1128-1134. PubMed ID: 28583617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
    Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL
    Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension.
    de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT
    Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid initiation of intravenous epoprostenol infusion is the favored option in patients with advanced pulmonary arterial hypertension.
    Kimura M; Tamura Y; Takei M; Yamamoto T; Ono T; Kuwana M; Fukuda K; Satoh T
    PLoS One; 2015; 10(4):e0121894. PubMed ID: 25844932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial.
    Tapson VF; Torres F; Kermeen F; Keogh AM; Allen RP; Frantz RP; Badesch DB; Frost AE; Shapiro SM; Laliberte K; Sigman J; Arneson C; Galiè N
    Chest; 2012 Dec; 142(6):1383-1390. PubMed ID: 22628490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perioperative Management of Pregnant Women With Idiopathic Pulmonary Arterial Hypertension: An Observational Case Series Study From China.
    Zhang J; Lu J; Zhou X; Xu X; Ye Q; Ou Q; Li Y; Huang J
    J Cardiothorac Vasc Anesth; 2018 Dec; 32(6):2547-2559. PubMed ID: 29525197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension.
    Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ
    J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.